A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

I. Cherny, Nathan; Sullivan, Richard; Dafni, Urania; Martijn Kerst, J.; Sobrero, Alberto; Zielinski, Christoph; G.E. de Vries, Elisabeth; Piccart, Martine

doi:10.1093/annonc/mdv249

Public

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Published in Annals of Oncology • May 31, 2015

Authors:

Nathan I. Cherny

Richard Sullivan

Urania Dafni

Abstract

The value of any new therapeutic strategy or treatment is determined by the magnitude of its clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment options is derived from clinical research, in particular phase III randomised trials, which generate unbiased data...

Subject

Medicine

Clinical Oncology

Scale (ratio)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!